Report on

Operations of Industrial Affairs Site
Sanofi-aventis

Training Program
February 5, 2007 to March 12, 2007

Prepared by:
Habiba Khan
ID# 2003-2-70-001
Department of Pharmacy

Date of Submission:
April 22, 2007

East West University
Table of Content

Acknowledgement ................................................................. i
Origin of the report .............................................................. iii
Company overview .............................................................. v

<table>
<thead>
<tr>
<th>Departments</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>o Industrial Technology</td>
<td>1</td>
</tr>
<tr>
<td>o Information Solution</td>
<td>4</td>
</tr>
<tr>
<td>o Production</td>
<td>6</td>
</tr>
<tr>
<td>o Solid</td>
<td>7</td>
</tr>
<tr>
<td>- Tablet</td>
<td>8</td>
</tr>
<tr>
<td>- Capsule</td>
<td>15</td>
</tr>
<tr>
<td>o Sterile</td>
<td>19</td>
</tr>
<tr>
<td>o Liquid packaging &amp; manufacturing</td>
<td>28</td>
</tr>
<tr>
<td>o Packaging</td>
<td>34</td>
</tr>
<tr>
<td>o CPR</td>
<td>39</td>
</tr>
<tr>
<td>- Penicillin</td>
<td>40</td>
</tr>
<tr>
<td>- Cephalosporin</td>
<td>47</td>
</tr>
<tr>
<td>- Rifampicin</td>
<td>52</td>
</tr>
<tr>
<td>o Hoechst Marion Roussel</td>
<td>56</td>
</tr>
<tr>
<td>o Industrial Quality &amp; Compliance</td>
<td>58</td>
</tr>
<tr>
<td>o Quality Control</td>
<td>62</td>
</tr>
<tr>
<td>o Quality Assurance</td>
<td>70</td>
</tr>
<tr>
<td>o Quality Assurance Regulatory Liaison</td>
<td>75</td>
</tr>
<tr>
<td>o Analytical Support and Analytical Development</td>
<td>77</td>
</tr>
<tr>
<td>o Microbiology</td>
<td>83</td>
</tr>
<tr>
<td>o Warehouse</td>
<td>87</td>
</tr>
<tr>
<td>o Engineering</td>
<td>93</td>
</tr>
<tr>
<td>o Health Safety and Environment</td>
<td>96</td>
</tr>
<tr>
<td>o Human Resource Management</td>
<td>100</td>
</tr>
<tr>
<td>o Major Findings</td>
<td>103</td>
</tr>
<tr>
<td>o Conclusion</td>
<td>107</td>
</tr>
</tbody>
</table>
Acknowledgement
The report could have been created, tested and revised without the assistance of a large number of interested professionals. I take pleasure in acknowledging the important contributions made by the following organizations and individuals.

**Sanofi-aventis**

The Plant Human Resource Manager, Dilruba Khan deserve special mention for her role in this activity, for providing information regarding the company and its activities and also for helping through out the period of making the report. Then I would like to thank, Mr. Mahbubul Haque, Director Industrial Affairs; Mr. ABM Anwar Hussain, Director Industrial Quality & Compliance and Md. Muin Uddin Mazunder, Plant Manager, for providing valuable information regarding the site activities and also for providing their precious time. I am also grateful to Mr. M. Nasir Uddin, Director Business Development & Support for his active support and cooperation.

**East West University**

I want to thank my respective teacher Dr. Bidyut Kanti Dutta who inspired me to make the report. His inspiration helped me to get attached to the company, which in turn will help me in my professional life.
Origin of the Report
Origin of the Report

The study will help to gain work experience in the professional field. Thus the study relies on practical, real world situation to develop my skills and ability to analyze the working environment in which Sanofi-aventis operates.

Scope of the Study

1. Understanding the basic concept of manufacturing quality products
2. Helping to develop control measures for various functions
3. Testing my skills in communicating analysis, conclusion and recommendation
4. Understanding the in-plant environment of the pharmaceutical industry
Company Overview
Introduction

Number one Pharmaceutical Company in France and in Europe, number three worldwide sanofi-aventis has been positioned as a key player in the healthcare. The Group was set up more than 30 years ago.

Their business consists of discovering, developing and providing physicians and patients throughout the world with innovative, effective, well-tolerated and high-quality treatments, whilst maintaining the economic performance levels that will permit them to continue this undertaking.

As a global industry leader Sanofi-aventis seek to conquer and prevent disease by bringing to market innovative pharmaceuticals, vaccines, therapeutic proteins and diagnostics. Aventis pharma was created as a part of the 1999 business combination of Hoechst and Rhone-Poulenc to form Aventis SA, one of the world's leading life sciences companies. Aventis Pharma concentrates its efforts on strategic brands that meet growing patient needs and contribute to a long-term sales growth. With 2001 sales of 15.168 billion euro (excluding sales of diagnostics), Aventis Pharma contributes three-quarters of the life sciences sales of Aventis SA. The Aventis Pharma prescription drug business is investing about 2.98 billion euro a year in Drug Innovation and Approval, one of the industry's largest R&D budgets.

History of Aventis

In 1830 in London, John May, a young, talented employment seeker got a job with chemist Charles Price. By 1834, he left the company and formed his own firm with partnership JI Picket and TS Grimwade. Next year Mr. Picket died and Mr. Grimwade retired in 1839. Same year, a few months later William Garrad Baker, 24 an apprentice in his
father’s business and druggist joined May to start a new company and bought own premises at Golden Wharf. Baker started to look after manufacturing and dispatch while May was dealing with London Wholesale Market. Soon the introductory part of a future global company was founded. During First World War May & Baker became stronger through association with Poulenc Feres a reputed manufacturer of arsenic compounds. In 1927, Poulenc bought over 90% of May & Baker’s ordinary share and ended up with 85% of May & Baker’s total capital. Poulenc established its name in place of May & Baker. Shortly, Poulenc Frers merged with the Society Chemical des Usines du Rhone in France. In 1928, Rhone-Poulenc, became the largest manufacturer of organic chemicals in France with 3000 employees. In the following years, it became a story of mergers and acquisitions, the firm expanded all over the world under different names. In 1998 company decided to unify its global presence by the name of Rohne-Poulenc.

Bangladesh scenario

**Tongi Site**

**Site activities include production of drug products and distribution**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Site area</td>
<td>105600 m2</td>
</tr>
<tr>
<td>Plant area</td>
<td>18156 m2</td>
</tr>
<tr>
<td>Head count</td>
<td>396 nos.</td>
</tr>
<tr>
<td>Export</td>
<td>3 countries</td>
</tr>
</tbody>
</table>

**Capacity**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tablet</td>
<td>1850 mio</td>
</tr>
</tbody>
</table>


Capsule 396 mio
Liquid 18.7 mio
Cream/ ointment 6.40 mio
Suppositories 10.4 mio
Liquid sterile 30.0 mio
Sterile powder 8.40 mio
Powder for suspension 9.80 mio

Site History

- 1960  Incorporation as a joint venture company- Pakistan Pharmaceutical Industry with May & Baker owning 60% and Pakistan Industrial Development Corporation 40% shares.
- 1962  Production and marketing of Largacil, Flagyl, Stemetil, Phenergan etc
- 1971  Independence of Bangladesh
- 1972  Renamed as Bangladesh Pharmaceutical Industry
- 1981  Started animal health & nutrition and agrochemical business
- 1986  Renamed as Rhone-Poulenc Bangladesh Limited
- 1990  Development of sales of Profenid, Peflacine, Imovane etc.
- 1995  
  - Renamed as Rhone-Poulenc Rorer Bangladesh Limited
  - Animal health & nutrition and agrochemical business reformed as a new company- Rhone-Poulenc Agrovet Bangladesh Limited
  - Acquisition of Fisons
- 1997  GMP upgrade and implementation of GMPs on site
- 1998  Started Qualification & Validation activities
- 1999  Merger of Rhone-Poulenc Rorer and Hoechst Marion Roussel to form a new company- Aventis Pharma
- 2001  Complete transfer of Fisions and HMR products on site
- 2002  Complete technology transfer of Amaryl and Tritace from Scopitto, Italy
- 2004  
  - Commendable achievement of the site in IACS Audit-
  "Green Site"
  - New company – Sanofi - aventis

**Background**

Sanofi Aventis is the 3rd largest pharmaceutical company in the world and no. 1 in Europe. In Bangladesh it has 3 legal entities and represents the largest multinational pharmaceutical manufacturing operation in the country.

Since its inception (45 years ago) the Tongi site with its new construction and up gradation has turned into an internationally GMP compliant recognized as a green site with its own glory and natural beauty.

Tongi industrial affairs team has put forth their best effort to achieve the goal and is ready to meet any future challenge.

**Their Mission**

Aventis has a mission to become the BEST pharmaceutical company in the world by dedicating their resources, their talents and their energies to help improve human health and the quality of life of the people throughout the world.

**Their Objective**

Aventis has the objective to become one of the leading drug companies in the world through the success of strategic imperatives: Investment in research,
quality, and innovation in the services provided to all their customer. Aventis aims to satisfy the specific needs of medical community.

**Their Goal**

The goal of sanofi-aventis is to involve every employee with its success and its commitment to health care by developing their professional skills and talents, and by helping them build their careers within the Group.

**Their Values**

Sanofi Aventis has chosen to focus on seven key values in order to: create an environment where everyone is proud of the work of the employees and committed to Sanofi Aventis; capitalize on its cultural diversity and varied experiences; guide its behaviour in ways that build its competitive advantage by achieving excellence in performance.

**Empowerment**

Sanofi Aventis

♦ A sign of respect of people
♦ Achieve through powerful mission and transparent process
♦ Encourage and reward self-confidence and initiative
♦ Require accountability.

**Major Therapeutic Areas**

Their marketed product portfolio covers seven core therapeutic areas:

- Cardiovascular
- Thrombosis,
- Central nervous system,
- Oncology,
- Metabolic disorders
- Internal medicine
• And vaccines.

Strengths of Sanofi aventis

- Strong leadership
- House keeping
- Traditional safety culture
- Good discipline
- Occupational health

Qualification and Validation

1. Total no. of products 148: Level of process validation completeness
2. Total no. of process equipments 212: Level of process validation equipment qualification
3. Total no. of analytical methods 226: Level of analytical method validation
4. Total no. of lab equipments 82: Level of lab equipment qualification
5. Total no. of cleaning process 24: Level of cleaning validation completeness.

HSE compliances and site good practice

Site is compliant to local and global HSE rules.

Site good practices include

A. Top management involvement in the development and implementation of HSE action.
B. Excellent compliance check process against countries new laws and regulations.
C. Well implemented and maintained internal audits and HSE inspection programs.
D. Strong commitment of shop floor management in warehouse, correct use of PPE, good house keeping for technical areas and inside building.

Protection of environment

A. Waste water treated with effluent treatment plant before release into the outside environment.
B. Solid wastes are processed externally by outside contractor.
C. Emissions are within compliance.

Good practices

A. Site has automatic external defibrillator (AED) to attend emergency cardiac arrest problem.
B. Installed public address system.
C. Team for crisis management, emergency response, first aid and fire fighting.
D. Emergency preparedness.
E. Risk assessment review program.
F. Process monitoring and controls.
G. Review of HSE system.

HSE priorities

- Industrial safety
  o Implement explosive atmosphere (ATEX) directive regarding hazards.
  o Training on individual safety to employee.
  o Control occupational exposure.
- Environment protection
  o Reduction of solid waste by 1.6% from the baseline of 2004
  o Reduce use of water 10% from 2004 baseline
  o ISO 14001 certification.

- Property protection
  o Fire hydrant system upgrading.
Industrial Technology
IT deals with the following sectors

A. Validation
Criteria required for the manufacturing of quality products. e.g. compression pressure, rpm etc are validated after 2-3 batch of successful production and establishment as standard procedure for the product.

B. Qualification
Qualification is done on the basis of cGMP and HSE requirements.

C. Calibration
To detect whether the temperature, rate, humidity, air flow etc displayed on the respective instruments are correct or not.

D. Changing
Changing in any part of the procedure is done showing valid reason and then is approved in a meeting.

E. Deviation
Any deviation is recorded and then by doing investigation the cause is uncovered and correction methods or suggestions are also noted.

Functions of IT department

A. Design qualification
It is done the basis of following the three factors:
- Requirements of production
- Facilities available
- HSE profile

B. Installation qualification
Done the basis of protocol of the group. If any change occur, then it should be justified and conclusion should also be verified and approved.

C. Calibration qualification
Regularly all the equipments are calibrated.

D. Operational qualification
Trial batch is run, justified, verified and approved. On the basis of operational qualification SOP is prepared,
E. Performance qualification
Raw material (source, brand), weight (balance), batch manufacturing record, packaging materials, manufacturing instructions are under this qualification.

F. Addendum qualification
Every year calibration, maintenance or thorough checks up of the machines are done.
Class I: Calibrated within 6 months.
Class II: Quality will not be hampered but time dependent.
Class III: Reference instruments.
Class IV: Not time dependent.

G. Cleaning qualification
Microbial test and chemical identification tests fall under this category.

H. Computer system validation/ software validation/ hardware validation

I. Process robustness
It deals with statistical process control reducing the loss improving quality.

J. Room qualification

K. Analytical method validation

L. Validation master plan

M. Site validation master plan

N. Change control validation

O. Preventive maintanances

Training

Training programs are carried out on the following subjects:
- Administrative
- Management
- Technical
This system is present in the plant as well as in the head office. There is a special small room in the plant for IS, where the machines are kept from where the data are received from the head office and distributed and send to the head office.

There is a special software/ system in plant from where the data are automatically received by the server at particular time and then send to the head office.

Soft wares are also developed by this department and sometimes soft wares are also brought from abroad or from other companies.
Production
Solid
Two dosage forms are prepared in this section

1. Tablet
2. Capsule

**Tablet**

Tablets are solid dosage form with or without excipients, which are prepared by compression. Excipients may include diluents, binders, disintegration agents, and lubricants, sweetening agents, flavoring agents and coloring agents.

Processes of tablet manufacturing:
1. Granulation
2. Compression
3. Coating

**Granulation**

Granulation is the process in which powder particles are made to adhere to form large particles called granules. Granulation is carried out to confer fluidity, compressibility & uniformity of the powder systems.

There are two methods for the manufacture of granules.

- Wet granulation methods *(Most widely used method)*
- Dry granulation method

There are many methods also to make the tablet dosage form. The methods are:

- Direct compression
- Slugging
Flow chart of wet granulation

Raw materials are screening through the Vibratory Sifter

Mixing in the planetary mixer + solution is added prepared by silver son stirrer

Sizing through the multimill

Drying in the fluid bed drier

Blending

Ready for the compression

Coating

Packaging

Flow chart of dry granulation

This method is used for powders which require granulation and sensitive to moisture and water.

Raw material weighing
Dry mixing in double cone blender

Compaction by roller compactor

Slugging

Milling

Sieving

Final mixing (Lubrication)

Compression

**Direct compression**

This is the method used in Sanofi Aventis for manufacturing of tablet. The materials are directly compressed to form tablets. The steps for direct compression are:

Raw materials weighing

Drying

Crushing

Sieving
**Flowchart for overall tablet manufacturing practiced in Sanofi Aventis**

- Raw material store
- Dispensing
- Dry mixing → Paste addition → Wet granulation
  - Blending ← Sieving ← Drying
  - Compression → Tablet → Pass through metal detector → Uncoated tablet
    - Pass through detector
    - Coating → Coated tablet → Packaging

**Basic requirements for successful tablet manufacturing**

a. Design:
   - For separate operations, separate rooms are available
   - Air lock door system available
   - Separate entrances for personal and materials
- Floors and walls have no sharp edges preventing dust deposition.
- Floors and walls are painted by epoxy paint.

Rooms available in tablet section are:
1. Hand washing, shoe cover and gown wearing room
2. Office room
3. Solution preparation room
4. Coating room
5. Dispensing room
6. Store
7. Granulation room
8. Blending room
9. Equipment store
10. Compression room
11. Capsule filing room

b. Equipments:

List of equipments:

- Jaguar mixture granulator (India)
- Alliance fluid bed dryer (India)
- Apex mill (London)
- Rotopress compression machine
- Manesty BB3B compression machine (England, 38 punches, 2000 tab/min)
- Cadmach CMB4 compression machine (India, 36 punches, 1200 tab/min)
- Korcsh compression machine (Germany, 30 punches, 2400 tab/min, 80 rpm)
- Sejong capsule filling machine
- Clinocone blender (700 L)
- Sopphire fluid bed dryer (India)
- Saizone mixture granulator (India)
- Manesty oscillating granulator
- Sejong SFC 170 coating machine (Korea, 4-8 rpm)
- Sejong SFC 170 solution preparation tank

Following features are maintained for all the machines:

- Safety card (providing safety instructions to machine operators)
- List of authorized persons
- Labeling (describing state of operation, for example: machine label, to be cleaned, cleaned, under test etc)
- Machine log book
- Proper cleaning of the machine

c. Facility:

To maintain CGMP the following facilities are available:

- Adequate space
- PRW (purified water) supply
- HPS (high pressure steam) supply
- ICA (instrumental compressed air) supply
- Vacuum line
- Pressure differential gauze
- Positive air pressure

d. Personnel:

The workers operating the procedures are highly skilled. Some of them are even working here for 20-25 years.
They also properly maintain the PPI (personal protective equipment)

- Gowning
- Mask
- According to hazard of the product all the products are divided into 3 categories:
  - OEB (operational exposure band)- 2: cotton mask
  - OEB (operational exposure band)- 3: N-100 mask
  - OEB (operational exposure band)- 4: PAPR (powdered air purifying respirator)
- For blending: HFNP (half phase negative pressure)

# Parameters checked prior to tablet manufacturing:

- Proper cleanliness of all materials and room
- Check the room temperature, humidity and air pressure
- Proper mixing to distribute all ingredients uniformly
- Proper drying of the wet granules to adjust the moisture content of the granules.
- Proper selection of die and punch
- Compression pressure, speed of the machine.
- The prepared coating solution should be used within 72 hours and the compressed tablets should the coated with in 6 weeks.
- Tablet bed temperature, pan rotation, gun to bed distance, air temperature, atomized air pressure, pump speed and coating time.

**Parameters checked during In-process quality check**

In case of tablet compression the following parameters are checked

- Weight
- Height
- Hardness
- Disintegration
- Appearance
- In case of coating
- Molting or any spot
- Sticking
- Capping
- Broken edge
- Roughness

**Flow chart for tablet coating**

```
Tablet feeding → Spray of coating material → Simultaneous drying → Coated tablet
```

**Parameters checked prior to spraying coating solution**

- Pan rotation
- Gun to bed distance
- Negative pressure
- Inlet air temperature
- Outlet air temperature
- Atomizing air pressure
- Fluid return volume
- Pump speed

**Capsule**

Capsules are solid dosage forms in which the drug is enclosed in either a hard or soft gelatin shell. Gelatin shells are available in various sizes. Capsules shells have two parts; Body and Cap.
PROCESS INVOLVES:

Capsule shell in hopper
↓
Shall channel
↓
Station having two part upper punch and lower punch with negative air
Pressure collects shell from shell channel where cap remain at the top and
body at the bottom.
↓
By the action of negative pressure body and cap become separated.
↓
Upper punch contain cap and lower punch body
↓
Upper punch shrinks
↓
Lower punch goes to feeding channel
↓
By screw fill weight is adjusted
↓
Body of capsule filled with pellets
↓
Upper punch goes to faulty capsule ejection channel there faulty capsule is
ejected by
ejector and negative pressure.
↓
Both punch again close to each to each other
↓
Capsule again goes to final ejection unit there by means of ejector and
negative pressure capsule is ejected.
List of products manufactured in the Solid Production

Amaryl tablet 2×15×1 mg
Amaryl tablet 2×15×2 mg
Amaryl tablet 2×15×3 mg
Avomine tablet 50×10×25 mg
Flagyl tablet 50×10×200 mg
Flagyl tablet 50×10×400 mg
Imovane tablet 3×10×7.5 mg
Largactil tablet 10×10×100 mg
Largactil tablet 10×10×50 mg
Largactil tablet 50×10×25 mg
Macrocin tablet 10×10×250 mg
Macrocin tablet 5×10×500 mg
Macrocin granules for suspension 100 ml
Peflacine tablet 3×10×400 mg
Phenergan tablet 10×20×10 mg
Profenid- CR capsule 5×10×100 mg
Profenid- CR capsule 5×10×200 mg
Profenid-E tablet 5×10×100 mg
Profenid-E tablet 5×10×50 mg
Rovamycin tablet 5×4×3 mg
Secnidal granules for suspension 500 mg
Secnidal-DS tablet 5×2×1 gm
Spasmonil tablet 20×10×10 mg
Stemetil tablet 25×20×5 mg
Tritace tablet 2×14×2.5 mg
Tritace tablet 2×14×5 mg
Asec 3×10×10 mg capsule
Asec 3×10×20 mg capsule
Asec 3×10×40 mg capsule
Amizide tablet 20×10×50 mg
Asinar tablet 10×10×150 mg
Betanol tablet 10×10×50 mg
Betanol tablet 10×10×25 mg
Betanol tablet 10×10×100 mg
Butapan tablet 50×10×10 mg
Butapan tablet 10×10×20 mg
Ficlon SR capsule 5×10×100 mg
Ficlon tablet 10×10×25 mg
Ficlon tablet 10×10×50 mg
Fisat tablet 10×10
Fisat DS tablet 25×4
Firazin tablet 5×10×500 mg
Folfecap-CR capsule 3×10
Folfecap-CR plus capsule 3×10
Folfetab tablet 1×100
Folfetab tablet 1×1000
Fiambutol tablet 10×10×400 mg
Fiprox tablet 3×10×250 mg
Fiprox tablet 3×10×500 mg
Fiprox tablet 2×10×750 mg
Inflam tablet 10×10×200 mg
Inflam tablet 10×10×400 mg
INH tablet 1×100×300 mg
Meben tablet 5×6×100 mg
Mepadis tablet 20×10×50 mg
Metronid tablet 10×10×400 mg
Motilon tablet 50×10×10 mg
Salbutal tablet 50×10×2 mg
Salbutal tablet 50×10×4 mg
Sterile
Sterile section consists of three units:

1. Sterile area
2. Water plant
3. Packaging area

Criteria for sterile area

- Free from microorganism; outside air inlet allows air through 0.2 μ heap filter.
- Airlock system for materials and personnel entry.
- Positive pressure within the room.
- HVAC system.
- LAF for aseptic works.
- Special gowning for the personnel.

Description of the sterile area

Sterile areas are environmentally classified as A, B, C, D, 3, 2 and 1 area. Area used laminar air flow is described as Class A. Aseptic filling room is designated as Class B.

Aseptic manufacturing and terminal product filling area is designated as Class C. Terminal product manufacturing, bottle washing and other area of class 10000 is designated as Class D.

Change room for entering to manufacturing area is designated as Class 3. Material entry, inspection room, intermediate bulk store and packaging area are designated as Class 2.
Entry and exit procedure are described separately for different class area for maintenance of class environment and safety of personnel, equipment and products.

**Conditions required and maintained**

- Temperature in manufacturing area is 17-25 °C.
- Room air humidity is 30-60% RH.
- Room air pressure differential is ≥ 15 Pascal relative to surrounding area.
- Temperature, RH and differential pressure is checked at the beginning of any batch and at every 60 min interval.

**Filtration procedure used**

100 L solution is filtered under nitrogen gas pressure at 0.5 bar. Gassing of storage vessel is performed before and after filtration. The filtered solution is taken in to two 50 LSS storage vessels in equal distribution. The load is then sterilized. Integrity test is of the used cartridge filter and gas filter is performed before and after filtration according to SOP.

<table>
<thead>
<tr>
<th>Filter</th>
<th>Bubble Point Required</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cartridge Filter</td>
<td>3200</td>
</tr>
<tr>
<td>Gas Filter</td>
<td>1100</td>
</tr>
</tbody>
</table>

**Air flow system**

Air blower

Air flow

Floor

Hepa filter

Pre filter
### Parameters checked visual inspection of Ampules/ Bottles

1. Sealing
2. Volume
3. Fibers
4. Glasses
5. Foreign particles

<table>
<thead>
<tr>
<th>Type</th>
<th>Shape</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glass large</td>
<td>Large irregular shaped particle, sink to the bottom of the solution very rapidly.</td>
</tr>
<tr>
<td>Spicules</td>
<td>Long shiny, thin particles, sink rapidly.</td>
</tr>
<tr>
<td>Flakes</td>
<td>Flat, very thin and irregular in shape.</td>
</tr>
<tr>
<td>Specks</td>
<td>Rounded, sink slowly and usually sparks.</td>
</tr>
<tr>
<td>Fibers</td>
<td>Long, thin, straight, may float or sink.</td>
</tr>
<tr>
<td>Dust</td>
<td>Usually of dirt, fine particles and nearly float in the solution.</td>
</tr>
<tr>
<td>Colored particle</td>
<td>Black, red &amp; off-white, generally settle out but may float.</td>
</tr>
</tbody>
</table>

6. Sealing strength

### Equipments used

1. Rota ampule filling and sealing machine (Germany)
2. Linda steam sterilizer (Holland)
3. Getinge autoclave
4. Sanamij autoclave
5. Milliport filter
6. Greatide bottle washing machine
7. Hoong-A blister packing machine (Korea)
8. Stobel & Bousch ampule filling and sealing machine
9. Cozzoli ampule filling and sealing machine

Ampules or bottles are rejected when

1. Containing fibers, glass or any other foreign particles.
2. Having low volume, bad sealing, charring, and printing problem.

Flow chart for overall sterile product manufacturing
Process description of the sterile section

A. Receiving of RM
   i. Cleanliness of incoming drums, containers and bags
   ii. No materials entry except relevant to the product
   iii. QA approval

B. Dispensing of RM
   i. All materials of previous are removed
   ii. Shop is cleaned
   iii. Balance are calibrated
   iv. Temperature, pressure and humidity are checked every hour.

C. Manufacturing
   i. Mixing of WFT/ DW
   ii. Nitrogen gas passed to dissolve oxygen
   iii. pH adjusted (QA approval)
   iv. Temperature, pressure and humidity are checked every hour.

D. Filtration unit
   i. Filtration through 0.2μ sterilized cartridge

E. Filter integrity test (bubble test)
   i. Done before and after filtration

F. Sterilization
   i. Prevacuum
   ii. Steaming
   iii. Pulsing
   iv. Warming up
   v. Sterilizing
   vi. Drying
vii. Air inlet

G. Filling
   i. Headspace oxygen content ≤ 1.5%
   ii. Gas bulk solution with nitrogen gas
   iii. QC approval
   iv. Sample sent to microbiology lab

H. In process control
   i. Volume check
   ii. Nitrogen gas flow
   iii. Oxygen content

I. Shop clearance

J. Sterilization (product)
   i. Prevacuum three times
   ii. Heating
   iii. Sterilization
   iv. Post vacuum
   v. Pressure equalization

K. Leak test

L. Inspection

M. Packaging

N. QA approval
Flow chart for overall aseptic product manufacturing

Some factors given importance

1. Proper sterilization of all containers, equipments and other things used in manufacturing.
2. Proper room condition for the products.
3. Integrity test of cartridge filter by bubble point test.
5. Proper IPC for volume filled, nitrogen gas flow rate.
6. Leak test and proper inspection.
List of products manufactured in sterile section

1. Water for injection 10 ml
2. Water for injection 20 ml
3. Water for injection 5 ml
4. Flagyl 100 ml
5. Peflacine 5 ml
6. Voltalin 3 ml
7. Phenergan 2 ml
8. Profenid 2 ml
9. Largactil 2 ml
10. Avil 2 ml
11. Lasix 2 ml
12. Novalgin 2 ml
13. Asinar 2 ml
14. Stemetil 1 ml
15. Motilon 2 ml
16. Butapan 1 ml
17. Lignocaine 2 ml
18. Doloran 2 ml
19. Zepac 1 ml
20. Zepac 10 ml
21. Zepac 30 ml
22. Ficlon 3 ml
Liquid Packaging & Manufacturing
The following types of preparations are manufactured in this section

- Syrup
- Suspension
- Emulsion
- Elixir
- Cream
- Suppository

Factors which are given importance during manufacturing

- Proper dispensing
- Proper mixing, adequate mixing time and speed of vortex mixture
- Carefully transfer and filtration of the liquid
- Attractive appearance, color and flavor.

Name of equipments used

1. Rotary bottle washing machine (Taiwan)
2. Master bottle washing machine (India)
3. Bottle drying oven
4. Atomat liquid filling machine (India, 105 bottle/min)
5. King cap sealing machine (Germany)
6. Myth cap sealing machine
7. King bottle labeling machine (England)
8. Ink jet printer
9. Sarong suppository filling machine (Italy)
10. Sarong suppository sealing machine (Italy)
11. SSSJ manufacturing vessel (2250 L & 500 L)
12. Vortex mixture
13. Mono pump
14. Meta filter
15. SS cream storage vessel
16. SS bucket
17. Bowl scoop
18. Premier colloid mill
19. Kalix Dupuy cream filling machine (France)

List of products manufactured in this section

1. Anthisen cream 15 gm
2. Ascabiol emulsion 100 ml
3. Avil syrup 100 ml
4. Fisat suspension 60 ml
5. Flagyl suspension 60 ml
6. Inflam suspension 100 ml
7. Macrocin-T 2% lotion 30 ml
8. Metronid suspension 60 ml
9. Motilon pad. drops 15 ml
10. Motilon syrup 100 ml
11. Pevaryl cream 10 gm
12. Pevison cream 10 gm
13. Phenergan elixir 125 ml
14. Profinid gel 30 gm
15. Retin-A 0.05% cream 5 gm
16. Retin-A 0.05% cream 15 gm
17. Retin-A 0.05% cream 30 gm
18. Salbutal syrup 100 ml
19. Ficlon 12.5 mg suppository
20. Ficlon 50 mg suppository
21. Pevison cream 20 gm
22. Sandom drops 15 ml
23. Sandom suspension
24. Flagyl suppository 500 mg
25. Flagyl suppository 1000 mg

**Flow chart for oral syrup manufacturing**

Dispensing → Manufacturing → Filtering with meta filter → Storage vessel

Remaining portion

Buckner filter

**Flow chart for emulsion manufacturing**

Preparation of oil phase in one vessel

Preparation of water phase in another vessel

Addition of oil phase into water phase using centrifugal pump

Filtration with nylon cloth bag filter

Storage vessel
**Flow chart for oral liquid filling**

1. Empty bottle supply
2. Bottle washing
3. Filling
4. Cap sealing
5. Inspection

**Flow chart for suppository manufacturing**

1. Heating the vessel using steam at 70° C
2. Melting suppository mass with stirring
3. Cooling up to 40-45° C & adding the active ingredient
4. Sieving through 100 mesh sieve
5. Filling the cavities
6. Keeping the filled cavities in refrigerator for a day
7. Sealing, pre-welding temperature 143° C & sealing temperature 165° C
Flow chart for Cream Manufacturing

1. Preparation of oil phase in one vessel
2. Preparation of water phase in another vessel
3. Addition of oil phase to water through 100 mesh SS screen
4. Homogenization with continuous stirring
5. Passing through colloid mill into storage vessel
6. Cooling & filling
Packaging
Packaging materials used

Packaging materials are of two types:
Primary Packaging materials and Secondary Packaging Materials.

Primary Packaging materials used:
1. PVC
2. Aluminum foil
3. Clear & amber glass
4. Plastic spoon & syringe

Secondary Packaging materials used:
1. Printed cartoon
2. Outer
3. Liner
4. Labels
5. Leaflet
6. Printed tape

Packing forms

The following forms of packs available in this company:
1. Blister pack, used for tablet, capsule, ampule and vial
2. Strip pack, used for tablet and capsule
3. Amber glass bottle and ampule, used for liquid and injection
4. Clear glass ampule and vial, used for injectables
5. Aluminium collapsible tubes, used for cream and ointment.

Equipments used

1. Horn Noack Blister Packer (Germany)
2. E. TH Noack Blister Packing Machine (Germany)
3. Klockner Hansel Blister Packer (Germany)
4. Hoong A Blister Packer

Flow of Packaging procedure

Blister forming in the PVC film, using heat and pressure

Tablet filling

Mean while the printer fitted on the machine prints the alu

Sealing the blister with printed Aluminium

Printing batch no. and expiry date

Perforation

Cutting into individual blister pack

After blister preparation, in every 15/30 mins Leak Testing is performed using Leak Tester Apparatus

Visual inspection

Opening the printed cartoons

Filling certain number of strips into the cartoons

Filling the printed cartoons into the outers

Finally the cartoons are sent to warehouse after QA approval
Printing

Printing unit is essential to print batch no., mfg date, exp date, MPR of each product on label, cartoon, outer label etc. This unit consists of several overprinting machines that are semi automatic and manual:

1. Manna - Model- MAPL
2. Imprintamatic
3. MACs
4. Marico
5. Code-O – Matic

List of imported finished products packed in this section

1. Act-HIB injectables: Hoemophilus type B conjugate vaccine
2. Actonal 5 mg tablet
3. Azmacort inhaler 20gm
4. Avaxim 80: Hepatitis A child vaccine
5. Avamix 160: Hepatitis A vaccine (inactivated)
6. BCG vaccine, freeze dried
7. Compto 40mg injection
8. Compto 100mg injection
9. Clexane 2000 anti-Xa iµ/ 0.2ml
10. Clexane 4000 anti-Xa iµ/ 0.4ml
11. Clexane 6000 anti-Xa iµ/ 0.6ml
12. Clexane 8000 anti-Xa iµ/ 0.8ml
13. Endoxan ASTA 200mg
14. Endoxan tablet 50mg
15. Endoxan ASTA 500mg
16. Endoxan ASTA 1gm
17. Granocyte 34
18. Haemacel infusion
19. Holoxan injection 500 ml
20. Holoxan injection 1gm
21. Holoxan injection 2gm
22. Honvan injection
23. Honvan tablet
24. Immucyst injection 81mg
25. Insuman Basal 100 iu/ml
26. Insuman Rapid 100 iu/ml
27. Insuman Comb 100 iu/ml
28. Intal 5 inhaler
29. Lantus 100 iu/ml solution for injection
30. Meningoccal A+C vaccine
31. Nasacort AQ nasal spray
32. Paluther 80mg injection
33. Streptase 1500000iu
34. Succinyl siccum 500mg
35. Taxotere 20mg
36. Taxotere 80mg
37. Tetavax injectable: Absorbed Tetanus vaccine
38. Tilade inhaler
39. Transamin 500mg tablet
40. Transamin 250mg injection
41. Transamin 500mg capsule
42. Trimovax: Measles, mumps and rubella vaccine
43. Uromitexan 400mg injection
44. Verorab injectable: Rabies vaccine (vero cell)
CPR
Sanofi Aventis being a multinational pharmaceutical company in Bangladesh is renowned for manufacturing quality antibiotic products. It follows cGMP, and according to that the antibiotics has to be manufactured in isolated area from that of the non-antibiotics, to prevent cross contamination and resistance development. Sanofi Aventis has a separate building named CPR (C= Cephalosporin, P= Penicillin, R= Refampicin) where three different types of antibiotics are produced in three separate premises. These three premises are completely isolated from each other regarding the following the features:

- Different HVAC system
- Three different water treatment plant
- Gowning
- Manufacturing area
- Packaging
- Warehouse
- QC lab
- Waste management tank
- Non pharmaceutical activity
- Official activity

By following the above mentioned features Sanofi Aventis is able to maintain the quality of antibiotics. And that is why multinational company like Novartis and local company Beximco gave them the offer of toll manufacturing.

Penicillin Section

Types of products

1. Capsule
2. Tablet
3. Dry powder
4. Pediatric drops
5. Dry powder for injection
Equipments used

1. Drum blender (England)
2. Clinocone (India)
3. Cube mixture (England)
4. J.G Jackson & croikt granulator (England)
5. Apex Granulator (England)
6. Manesty oscillating granulator (England)
7. Manesty petrie dryer (England)
8. Manesty B3B (16 punch) rotary tablet machine (England)
9. Manesty B3B (23 punch) rotary tablet machine (England)
10. Manesty D3A rotary tablet machine (England)
11. Automatic film coating machine (Thailand)
12. Zanasi AZ20 capsule filling machine (Italy)
13. Zanasi AZ40 capsule filling machine (Italy)
14. Zanasi MG2 capsule filling machine (Italy)
15. Arenco auger filler
16. Hauser filling machine (Korea)
17. Getinge autoclave (Sweden)
18. Hot air depyrogenation oven (Taiwan)
19. Bottle dryer
20. Hoong A blister packer
21. Gansons strip packer (India)
22. E. Th Noack strip packer (Germany)
23. Imperial electric & gas appliances Co. dehumidifier
24. Automatic bottle labeling machine (Taiwan)
25. Rotary bottle washer
26. Strunck vial washing machine (Germany)
27. P+AM capsule filling machine (India)
Equipments used in Penicillin Lab

1. Polarimeter
2. Moisture analyzer
3. Chomato UV E cabinet
4. Hot water bath
5. Ultrasonic vibration
6. Karl fisher titrator
7. Disintegration tester
8. Dissolution tester
9. Friability tester
10. Vacuum oven
11. Unicom UV/Vis spectrophotometer
12. Genesis series IR
13. HPLC
14. Electronic balance
15. Refrigerator

Use of personal protection clothing and wears

A chart is made where the decisions are taken which parameters are to be maintained in which operations:

### Solid Manufacturing

<table>
<thead>
<tr>
<th>Shop</th>
<th>Operation</th>
<th>Cap</th>
<th>Mask</th>
<th>Arm Cover</th>
<th>Gloves</th>
<th>Shoes</th>
<th>Safety Glass</th>
<th>Ear Muff</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granulation</td>
<td>Dispensing</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Mixing</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Solution</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Process</td>
<td>Drying</td>
<td>Sieving &amp; blending</td>
<td>Cleaning</td>
<td>Hopper charge</td>
<td>Compression</td>
<td>In process test</td>
<td>Cleaning</td>
<td>Solution preparation (aqueous)</td>
</tr>
<tr>
<td>---------------------</td>
<td>--------</td>
<td>--------------------</td>
<td>----------</td>
<td>---------------</td>
<td>-------------</td>
<td>----------------</td>
<td>----------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Liquid & Cream Manufacturing

<table>
<thead>
<tr>
<th>Shop</th>
<th>Operation</th>
<th>Cap</th>
<th>Mask</th>
<th>Arm Cover</th>
<th>Gloves</th>
<th>Shoes</th>
<th>Safety Glass</th>
<th>Ear Muff</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oral liquid</strong></td>
<td>Dispensing</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Syrup preparation</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mixing</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Filter setting</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Filtration of syrup/elixir</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Filtration of suspension</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cleaning</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Topical liquid</strong></td>
<td>Dispersion of oil phase</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dispersion of aqueous phase</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Emulsification</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Transfer</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cleaning</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cream &amp; suppository manufacturing</strong></td>
<td>Dispersion of oil phase</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dispersion of aqueous phase</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Emulsification</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Homogenization</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>V</td>
</tr>
<tr>
<td></td>
<td>Transfer</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cleaning</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Sterile Manufacturing
Cleaning of Penicillin manufacturing area

Special Instructions followed for the cleaning purposes

1. Freshly prepared disinfectant or detergent solutions are used in the same day of preparation.
2. Non shedding materials are used for any cleaning purpose.
3. The safety of all equipment and products are ensured from dirt, water, detergent or disinfectant at the time of cleaning.

Types of cleaning and preparation of disinfectant solutions

a. Savlon solution (17.5 % v/v)
To prepare 1000 ml solution 175 ml of Savlon is added into 825 ml of PW
b. Dettol solution (2.5 % v/v)
To prepare 1000 ml solution 25 ml of Dettol is added into 975 ml of PW
c. Sodium Hypochlorite solution (0.25 % v/v)
To prepare 1000 ml solution 0.25% solution from a 5% solution, 50 ml of the 5% solution is mixed with 950 ml of PW.
b. The containers of the detergent or disinfectant solution are labeled properly with name, strength and date of preparation.

c. Cleaning is of two types: A) Normal B) Gross.

**Critical and acceptable parameters**

Savlon, Dettol, Hypochlorite and IPA solutions are prepared with care. Acceptable percentages are 17.5, 2.5, 1 & 70% respectively.

**Frequency:**
Savlon is used in first and third week and Dettol is used in second and forth week in the month. Sodium hypochlorite solution is used in case of gross cleaning.

**Room inspection checklist**

Parameters observed incase of room inspection are:

1. No insect dents etc within the room.
2. No dust, shoot, cob web, fungus etc on
   a. Equipment/ furniture/ cabinet
   b. Floor/ wall/ ceiling
   c. Door/ glass
   d. Extinguisher/ fire hose
   e. Diffuser/ return air grill
3. No crack, dent, blister, rust, deterioration of paint on:
   a. Equipment/ furniture/ cabinet
   b. Floor/ wall/ ceiling
   c. Door/ glass
4. Function of smoke detectors
5. No leakage from
   a. Water/ steam/ compressed air/ vacuum/ gases/ lubricant
6. No broken
   a. Electrical pheg socket/ swich
b. Conduit/ light cover
7. Proper label on equipment
8. Overall tidiness

Cephalosporin Section

Types of products

1. Capsule
2. Tablet
3. Dry powder for syrup
4. Pediatric drop
5. Dry powder for injection

Equipments used

1. Drum blender (England)
2. Rotogran
3. Rotary bottle washing machine
4. Bottle dryer
5. Rotary vial washer (Taiwan)
6. Getinge autoclave (Sweden)
7. Hot air oven
8. Imperial electric and gas oven
9. Zanasi AZ20 capsule filing machine (Germany)
10. Gansons strip packer
11. OTTO Hansel vial blister packer
12. Jaganberg Wene AG labeling machine (Germany)
13. Automatic bottle labeler

Equipments used in Cephalosporin Lab
1. UV/vis spectrophotometer
2. Analytical balance
3. Dissolution tester
4. Thermonic DT machine
5. Oven
6. Kerry ultrasonic bath
7. Thermonic bulk density apparatus
8. Dissolution tester six vessels
9. Refrigerator
10. Karl fisher titrator
11. Thermonic friabilator
12. HPLC
13. pH meter

Flow chart for capsule manufacturing and filling

Active ingredients, diluents, lubricants, excipients → Blending → Capsule shell

Capsule shell lock ← Capsule shell filling

QC

Polishing → Packaging → Store
Flow chart for manufacturing of dry powder for syrup

Sugar crashing \(\rightarrow\) Blending active ingredient, sugar & other ingredients \(\rightarrow\) Granulation

Bottle wash \(\rightarrow\) Bottle dry

Packaging \(\leftarrow\) Labeling \(\leftarrow\) Filling & sealing

Blending \(\rightarrow\) QC

Flow chart for manufacturing of dry powder for injection and pediatric drops

Vial washing \(\rightarrow\) Sterilization

Active ingredients

Filling \(\rightarrow\) Capping \(\rightarrow\) Counting & checking

WFI (ampule)

Final packaging \(\leftarrow\)

Printing & labeling

Cleaning of Cephalosporin manufacturing area
Preparation of solution:
- Savlon solution (17.5% v/v)
2L of PW was taken in a bucket and 880 ml Savlon was added. And then the volume was made upto 5 L with PW.

- Dettol solution (2.5% v/v)
3 L PW was taken in a bucket and 125 ml of Dettol was added. And then the volume was made upto 5 L with PW.

- Sodium Hypochlorite solution (1% v/v)
192 ml of the 3.25% solution was mixed with 808 ml of PW to make the volume 1 L.

- Sodium Lauryl Sulfate solution (0.5% w/v)
500 ml of Sodium Lauryl Sulfate was mixed with 1 L PW.

- Sodium bicarbonate solution (10% w/v)
10 gm of Sodium bicarbonate powder was mixed with 1 L PW.

- IPA (Iso propyl alcohol) solution (70% v/v)
700 ml of IPA was mixed with 1 L PW.

Container:
Disposable drum, polyethene bag etc are cleaned by 10% sodium bicarbonate or 3% ammonia.

Gowning:
100 ml of 10% sodium bicarbonate or ammonia in washing tank, MOP solution and IPA is sterilized by 0.2 μ cartridge filter.

Some special features:
Fumigation: To revalidate the aseptic area fumigation is done by 37% formaldehyde with water in 1:1 ratio. As fumigation is highly carcinogenic fumigation is done at least twice in a year according to corporate guideline. Sanofi Aventis is able maintain the aseptic area by taking precaution other than fumigation such as proper HVAC, LAF, personnel etc.
Decontamination: Antibiotic molecules present in the waste is treated by; first it is decontaminated, i.e. the β-lactum ring is broken down by adding 1.5 L of 25% ammonia solution twice daily on working days.

**Parameters checked in Cephalosporin Lab to maintain the quality of the product**

In case of syrup/ suspension/ cream/ injectables:

1. Appearance
2. Odor
3. Identity
4. Color/ particulate matter
5. Average weight/ volume
6. Preservatives
7. pH
8. Miscibility with water/ consistency/ viscosity
9. Nitrate/ RI
10. Weight per ml
11. Microbial content/ Endotoxin test
12. Moisture/ water
13. Assay

In case of Raw Materials:

1. Appearance
2. Solubility
3. Identification
   a. IR test
   b. Sodium test
4. Clarity and color of solution
5. pH
6. Water (Karl Fisher Method)
7. Reconstituted solution
8. Assay
9. Sterility test
10. Bacterial endotoxin test
11. Particulate matter test
12. Particle size:
   a. 100% pass ____ mm sieve
   b. 73% pass ____ mm sieve
   c. 55% pass ____ mm sieve
13. Specific optical rotation
14. Absorbance
15. Sulphated ash
16. Related substances
17. N,N-Dimethylamine

In case of Capsule:
1. Appearance
2. Identity
3. Disintegration time
4. Weight of 20 capsules
5. Individual weight of 20 capsules
6. Weight % deviation from average weight
7. Moisture content
8. Assay
9. Chemical potency
10. Stated dose
11. Uniformity of weight

Rifampicin Section

Types of products

1. Capsule (no longer manufactured)
2. Tablet
Equipments used

1. Cadmill (India)
2. Drum blender
3. Rotogran MK III (England)
4. Sapphire fluid bed dryer
5. Jaguar high speed mixer granulator (India)
6. RAMA COTA coating machine (Thailand)
7. Manesty RD3 (16 punch) rotary tablet machine (England)

List of products manufactured in CPR section

1. Enocef injection + Ligno 500 mg IM vial
2. Enocef injection + Ligno 250 mg IM vial
3. Enocef injection + Ligno 1 gm IM vial
4. Enocef injection + Ligno 1 gm IV vial
5. Enocef injection + Water 250 mg IV vial
6. Enocef injection + Water 500 mg IV vial
7. Epilim chrono 200 tablet
8. Epilim chrono 300 tablet
9. Epilim chrono 500 tablet
10. Epilim syrup
11. Ficillin cap 250 mg
12. Ficillin paed drop
13. Ficlox cap
14. Ficlox inj + water
15. Ficlox paed drop
16. Ficlox syrup
17. Fimoxyclav inj 0.6 gm
18. Fimoxyclav inj 1.2 gm
19. Fimoxyclav syrup
20. Fimoxyclav tab 375 mg
21. Fimoxyclav tab 625 mg
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>22.</td>
<td>Fimoxyl 250 mg tablet</td>
</tr>
<tr>
<td>23.</td>
<td>Fimoxyl 500 mg tablet</td>
</tr>
<tr>
<td>24.</td>
<td>Fimoxyl cap 250 mg</td>
</tr>
<tr>
<td>25.</td>
<td>Fimoxyl cap 500 mg</td>
</tr>
<tr>
<td>26.</td>
<td>Fimoxyl DS syrup</td>
</tr>
<tr>
<td>27.</td>
<td>Fimoxyl inj + water 500 mg</td>
</tr>
<tr>
<td>28.</td>
<td>Fimoxyl inj + water 250 mg</td>
</tr>
<tr>
<td>29.</td>
<td>Fimoxyl paed drop</td>
</tr>
<tr>
<td>30.</td>
<td>Fimoxyl syrup</td>
</tr>
<tr>
<td>31.</td>
<td>Firifam tab 450 mg</td>
</tr>
<tr>
<td>32.</td>
<td>Firifam tab 150 mg</td>
</tr>
<tr>
<td>33.</td>
<td>Firifam cap 250 mg</td>
</tr>
<tr>
<td>34.</td>
<td>Fluxon cap 500 mg</td>
</tr>
<tr>
<td>35.</td>
<td>Oracin 'k syrup</td>
</tr>
<tr>
<td>36.</td>
<td>Oracin 'k tablet 250 mg</td>
</tr>
<tr>
<td>37.</td>
<td>Oracin 'k tablet 500 mg</td>
</tr>
<tr>
<td>38.</td>
<td>Pen-V 500 mg tablet</td>
</tr>
<tr>
<td>39.</td>
<td>Pen-V syrup</td>
</tr>
<tr>
<td>40.</td>
<td>Pen-V tablet</td>
</tr>
<tr>
<td>41.</td>
<td>Rifazid 300 + Z tablet</td>
</tr>
<tr>
<td>42.</td>
<td>Rifazid 450 + Z tablet</td>
</tr>
<tr>
<td>43.</td>
<td>Rifazid tablet 300 mg</td>
</tr>
<tr>
<td>44.</td>
<td>Rifazid tablet 450 mg</td>
</tr>
<tr>
<td>45.</td>
<td>Rifazid tablet 150 mg</td>
</tr>
<tr>
<td>46.</td>
<td>Sefdar cap 500 mg</td>
</tr>
<tr>
<td>47.</td>
<td>Sefdar cap 250 mg</td>
</tr>
<tr>
<td>48.</td>
<td>SefdarDS syrup</td>
</tr>
<tr>
<td>49.</td>
<td>Sefdar inj + water 500 mg</td>
</tr>
<tr>
<td>50.</td>
<td>Sefdar inj + water 1 gm</td>
</tr>
<tr>
<td>51.</td>
<td>Sefdar inj + water 250 mg</td>
</tr>
<tr>
<td>52.</td>
<td>Sefdar paed drop</td>
</tr>
<tr>
<td>53.</td>
<td>Sefdar syrup</td>
</tr>
<tr>
<td>54.</td>
<td>Sefrox 750 inj</td>
</tr>
</tbody>
</table>
55. Sefrox syrup
56. Sefrox 125 tablet
57. Sefrox 250 tablet
58. Sefrox 500 tablet

**List of products manufactured in this section for other companies**

**Product list of Beximco**

<table>
<thead>
<tr>
<th>Product name</th>
<th>Dosage form</th>
<th>Active ingredient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arixon</td>
<td>IV injection 250 mg</td>
<td>Ceftriaxone Sodium</td>
</tr>
<tr>
<td></td>
<td>IV injection 500 mg</td>
<td>Sterile</td>
</tr>
<tr>
<td></td>
<td>IV injection 1 gm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IM injection 250 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IM injection 500 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IM injection 1 gm</td>
<td></td>
</tr>
<tr>
<td>Enytracef</td>
<td>Injection 250 mg</td>
<td>Cephradin with Arginine</td>
</tr>
<tr>
<td></td>
<td>Injection 500 mg</td>
<td>Sterile</td>
</tr>
<tr>
<td></td>
<td>injection 1 gm</td>
<td></td>
</tr>
</tbody>
</table>

**Product list of Novartis**

<table>
<thead>
<tr>
<th>Product name</th>
<th>Dosage form</th>
<th>Active ingredient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Megion</td>
<td>IV injection 250 mg</td>
<td>Ceftriaxone Sodium</td>
</tr>
<tr>
<td></td>
<td>IV injection 500 mg</td>
<td>Sterile</td>
</tr>
<tr>
<td></td>
<td>IV injection 1 gm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IM injection 250 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IM injection 500 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IM injection 1 gm</td>
<td></td>
</tr>
</tbody>
</table>
Hoechst Marion Roussel
The Hoechst Marion Roussel building is a complete unit for solid dosage form. Mainly tablet is manufactured here, with includes compression, coating, packaging, and the sugar coated tablets are manufactured in only this section of the company. HMR building is well equipped with proper production facilities.

**Equipments used**

1. Sruti dry/wet granulating machine (India)
2. Sapphire fluid bed dryer (India)
3. Diosna mixture granulator
4. Alexander wet screening machine
5. Electric dryer
6. Frewitt-Zimmermann oscillator
7. Cadmach roll compactor
8. Manesty rotapress MKII compression machine (England)
9. Cadmach CMB 4 tablet compression machine (India)
10. Heracus TU 2 drier
11. Leak test apparatus (India)
12. Colloid mill
13. UPS blister packer machine
14. Jaguar strip sealing machine (India)

**List of products manufactured in this section**

1. Avil tablet 22.7 mg
2. Avil retard tablet 75 mg
3. Daonil tablet 5mg
4. Lasix tablet 40 mg
5. Frisium tablet 10 mg
6. Trentol tablet 400 mg
Industrial Quality & Compliance
IQC Department is very important for a pharmaceutical industry to maintain GMP. The concept of total quantity management and total quality control refers to the process of striving to produce a perfect product by a series of measures requiring an organized afford by the entire company to prevent or eliminate errors at every stage in production.

Although the responsibility for assuring product quality belongs principally to IQC, it involves many departments and disciplines within the company. To be effective it must be supported by a team effort.

The IQC dept. is a vital part for a pharmaceutical industry since it controls and assures for quality of the products staring from the raw materials to the finished product till the customers consume it.

All kinds of necessary steps are taken by this department to serve a quality product to the end users.

A pharmaceutical product must satisfy certain standards to claim its quality. The main criteria of any drug, in dosage form are:

a. Safety
b. Potency
c. Efficiency
d. Stability
e. Acceptance
f. Regulatory compliance
**Industrial quality manual**

**IQC performance**

- KPI: Right first time
- KPI: Validation achievement
- KPI: Product technical complaint
- KPI: Quality cycle time
- KPI: Quality cost

**The IQC department is divided into 5 sections**

1. Quality control
2. Quality assurance
3. Analytical support and analytical development
4. Quality assurance regulatory liaison
5. Microbiology
Equipments used in IQC Lab

1. Hardness tester
2. Friability
3. Automatic refractometer
4. Vacuum oven
5. Total organic carbon analyzer
6. Total organic carbon generator
7. Water purifier
8. Conductivity meter
9. Dissolution tester
10. Disintegration tester
11. Analytical balance
12. Karl fisher
13. Viscometer
14. Potensiometric titrator
15. Electromagnetic sieve shaker
16. TLC
17. Centrifuger
18. Alliance HPLC
19. Shimadzu HPLC
20. Vacuum pump
21. Moisture balance
22. FTIR
23. Micro melting point apparatus
24. UV/vis spectrophotometer
25. Electric oven
26. Refrigerator
27. Hotspot furnace (oven sulfated ash)
28. Drying oven
29. Muffle furnace
30. Magnetic stirrer hotplate
31. Dissolution oxygen meter
32. Stability chamber  
33. Ultrasonic bath  
34. Compactometer  
35. Eight channel plastic counter  
36. LAF cabinet  
37. Fume cupboard  

**Quality Control Department**

QC is one of the vital factors in any pharmaceutical company. Quality control can be defined broadly as the regular control of quality ensured by pharmacist, and technicians responsible for the acceptance or rejection of incoming raw materials and packaging components, in the Q. C for in-process tests and inspections, to assure that systems are being controlled and monitored.

Quality control, therefore, includes not only the analytical testing of the finished product, but also the assessment of all operations beginning with the receipt of raw materials and continuing throughout the production and packaging operations, finished product testing, documentation, surveillance. QC must select vital points to include parameters for effective quality assurance.

**QC is responsible for**

1. Analytical testing of RM  
2. Inspection of PM  
3. In-process control (IPC)  
4. Testing of finished products

**Analytical tests performed for RM**
1. Appearance
2. Odor
3. Solubility
4. Identity
5. pH
6. Water content
7. Residue on ignition
8. Heavy metals
9. Sulfates
10. Assay
11. Limit of fluoroquinolic acid
12. Chromatographic purity
13. Refractive index
14. Acidity/alkalinity
15. Viscosity

Packaging material control

For ensuring quality of the end product the packaging components must be of right quality. For this the following parameters are checked:

A. PVC/PE/PVdC film for blister packing
   1. appearance
   2. visual inspection
   3. dimensions
   4. adhesion of PVdC coating
   5. presence of PVdC coating

B. Unprinted polythene laminated aluminum foil
   1. Appearance
   2. Visual inspection
   3. Dimensions
   4. GSM of foil
   5. GSM of polythene film
6. Adhesion of polythene film

C. Label

1. Appearance

2. Visual inspection for detection

- Critical:
  - Layout, color or text not as approved at work

- Major:
  - Printing missing, print smeared, partial print

- Minor:
  - Shade variations outside agreed tolerance
  - High print outside agreed tolerance
  - Light print outside agreed tolerance
  - Sport or streaks in print outside agreed tolerance
  - Partial print
  - Print blurred

3. Text

4. Dimension

5. Material

D. Printed cartons

1. Appearance

2. Visual inspection

- Critical:
  - Foreign carton, layout, color or text not as approved at work

- Major:
  - Printing missing, print smeared, partial print

- Minor:
  - Shade variations outside agreed tolerance
  - High print outside agreed tolerance
  - Light print outside agreed tolerance
  - Sport or streaks in print outside agreed tolerance
3. Text
4. Dimension
5. Material
6. Squareness of carton
7. Performance work
8. Color fastness

E. Leaflet
1. Appearance
2. Visual inspection for detection
   - Critical:
     o Layout, color or text not as approved at work
   - Major:
     o Printing missing, print smeared, partial print
   - Minor:
     o Shade variations outside agreed tolerance
     o High print outside agreed tolerance
     o Light print outside agreed tolerance
     o Sport or streaks in print outside agreed tolerance
     o Partial print
     o Print blurred

3. Text
4. Dimension
5. Material

F. Printed aluminium/ polyethylene foil:
1. Appearance
2. Visual inspection for detection
   - Critical:
• Layout, color or text not as approved at work
  • Major:
    o Printing missing, print smeared, partial print
  • Minor:
    o Shade variations outside agreed tolerance
    o High print outside agreed tolerance
    o Light print outside agreed tolerance
    o Sport or streaks in print outside agreed tolerance
    o Partial print
    o Print blurred

3. Dimensions
4. GSM of foil
5. GSM of polythene film
6. Adhesion of polythene film

G. Alu collapsible tubes:
1. Appearance
2. Text
3. Visual inspection for defects
  • Critical:
    o Incorrect print color, foreign tubes, incorrect cap
  • Major A:
    o Badly dented or damaged tube
    o Caps internal contamination with foreign matter
    o Thread metal nozzle containing loose metal silvers or particles
    o External enamel cracking or flaking
    o Internal contamination of tube with dirt or foreign matter
    o Cap missing
  • Major B:
    o External contamination with dirt or foreign matter
    o Unevenness on outer surface
• Minor:
  o Minor dents in tube bodt
  o Color or print outside agreed tolerance
  o Decorating defect visible on close examination

4. **External lacquered**
5. Cleanliness check
6. Dimension
7. Average weight
8. Capacity
9. Material
10. Sealing condition of nozzle top
11. Crimping condition of tube
12. Performance check
   • Spike
   • Cap

H. Ampule closed, clear, type 1 glass printed
1. **Appearance**
2. Symmetry and firmness check
3. Text
4. Visual inspection for defects
   a. Mfg defects
   b. Printed defects
5. Dimensions
6. Hydrolytic resistance
7. Break force

I. Bottle for Flagyl 100ml injection type II glass
1. Appearance
2. Visual inspection
3. Dimensions
4. Weight
5. Capacity
6. Hydrolytic resistance

J. Vials, clear type 1 glass for antibiotic injection (tubular)
   1. Appearance
   2. Visual inspection
   3. Dimensions
   4. Weight
   5. Capacity
   6. Hydrolytic resistance

Other than these, tests are also performed on several other materials (according to Standard Methods):
   1. Ampule closed, amber, type I glass printed
   2. Unprinted alu foil, coated for blister packaging tablets and capsules
   3. R. O. P. P alu cap for pharmaceutical bottles
   4. Glass bottle for oral preparation and vial for injection, type III glass
   5. HDPE plastic container
   6. PVC film for blister packing
   7. Rubber plug for injection/bottle vial
   8. Flip off seal for injection Flagyl bottle/vial
   9. Printed alu. foil, coated for blister packing tablets, capsule and injection
   10. Plastic plugs
   11. Disposable plastic syringe with needle
   12. Unprinted PVC/alu./OPA foil for blister packers

In Process Control

IPC is done during the course of manufacturing which aims to ensure that products manufactured complies with the specifications of Sanofi Aventis:

A. Tablet section:
   1. Weight variation
   2. Disintegration
3. Friability  
4. Dissolution  
5. Hardness  
6. Thickness  
7. Diameter

B. Capsule section:  
1. Moisture content  
2. Weight variation  
3. Sealing

C. Sterile:  
1. Supervised by operators whether they comply or not with the SOP’s

D. Packaging section:  
1. Label check  
2. Carton check (randomly)  
3. Blister sealing check/leak check

E. Syrup section:  
1. Flavor  
2. pH  
3. Viscosity  
4. Assay  
5. Microbial counts  
6. Volume  
7. Weight per ml at 20° C

**Quality control for finished products**

These tests are performed to determine compliance with specifications and hence are critical factors for the QA department. These testing procedures are
established in on an equally sound and recognized basis, and the entire system is enormous. In Sanofi Aventis the following parameters are checked:

1. Lot no./ Batch no.
2. Date of receive
3. Date of test
4. Appearance
5. Odor
6. Identity
7. Length/diameter (mm)
8. Thickness (mm)
9. Presence of coating
10. Friability
11. Percent stated dose
12. Calculated weight (gm)
13. Total weight of 20 tab/cap content (gm individual)
14. Average weight (gm)
15. Maximum individual deviation
16. Disintegration
17. Dissolution
18. Related substances
19. Moisture content
20. Assay

Quality Assurance Department

Drugs which do not comply to the given standards, are considered as substandard. Drugs become substandard due to

(1) Faulty formulation,
(2) Faulty processing,
(3) Unsatisfactory packaging and unfavorable conditions of handling during transportation or storage. because drugs are used in human beings, Therefore their quality assurance is essential.
Quality assurance program is the devise and implement systems and procedures that provide a probability that each dose or package of a product will have homogenous characteristics and properties to ensure both safety and efficacy of the formulation.

In order to achieve the quality objective a wide range of activities are involved

A. Ensuring fulfillment of regulatory requirements
B. Establishment specification and control procedures for all starting materials, intermediates and finished products
C. Arranging quality audit visits to suppliers and self inspection
D. To ensure implementation of GMP
E. Establishing manufacturing methods and SOP's and their regular up gradation
F. Communication of every aspects relating to quality to all relevant persons for early positive action
G. IPC and their implementations
H. Identification of high risk areas of contamination or action
I. Batch determination system, reviewing data and assaying problems
J. Working closely with relevant department for validation of equipment, process, control procedures and critical systems
K. Marketing complaints for actions
L. Rejection trend analysis and actions
M. Identifying problems and positive actions for error cause removal
N. Ensuring adequate training programs

Documentation

During the course of producing a pharmaceutical product, numerous documents and records are generated. Each batch is assigned a specific code or lot numbers which include data on each significant phase of production, control and distribution.
The batch record provides a historical blueprint of every step, starting from the receipt of chemical raw materials and packaging components. Recording charts or computer printouts of significant operations such as autoclaving, drying, air-particulate monitoring, lyophilizing, etc; all are the part of the batch history.

Each required document must be checked for completeness and accuracy. When the batch is released, accurate shipping records must be maintained.

Documentation is a vital part of GMP to get approval from not only our country but also to get approval from FDA. In Sanofi Aventis first a Process Order (material list) is prepared then at last from QA a transfer note is given for release. After that all the documents are kept for more than one year than the expiry date of the product.

Parts of documentation:
- PTC (product technical complaint)
- Change control
- Deviation
- OOS (out of specification)

Change control

Operation procedures of change control

It is done for any permanent change

According to need a change order can be raised by any department (for example: solid section wants to reduce batch size of product from 120 kg to 70 kg) Sent to QA
A committee is formed and a meeting is called and decision is taken that what should be done for the change

Batch manufacturing record, packaging record, validation are checked

Long term stability tests are performed and then the product is marketed

Meeting minutes is prepared and distributed

In case of batch size change regulatory requirement is not needed but in case of formula change is it required.

After the approved conditions are implemented then the change control is closed

If the conditions are not implemented then according to SOP after six months the change control will be closed and if needed again a new change control has to be raised.

Product technical complaints (PTC)

In case of a problem in printing or any other example: the batch no. is not clear on the strip and was detected by IPC and then those are checked thoroughly. Then by doing statistical analysis the percent is verified and if it is within the limit then the batch can be marketed.
Now, if any complaint comes from market then a form is filled and team of two is formed combining a person from QA and one from production. And all the documents are filed and distributed to the respective/related authorities.

**Out of Specification (OOS)**

Operation procedures of OOS

OOS is raised when any deviation occurs. For example:

A batch of Flagyl tablet was supposed to be of 390~410 mg but was found of 380 mg, so a OOS is raised

A investigation team is formed

A cross functional team is also formed

A letter is send to Director Industrial Quality and Compliance

Recommendation will be made to close the OOS within 20 days

Within 7 days the investigation is complete

The root is identified

The team decides how to reduce the loss
The director IQC signs the copy and the OOS is closed

A copy of it is send to plant manager

A copy of the OOS is attached with each copy of BMR of that batch

Deviations

If a punch or a hopper breaks or a machine becomes out of order or any other this type of problem occurs then deviation rises. For example:

Purified water of Penicillin section has high conductivity

Deviation raised by engineering department

Water taken from Cephalosporin section

Again water conductivity tests are performed.

Quality Assurance Regulatory Liaison

QARL is a very important section of QA department. Major responsibilities of this section are:
A. Establishing drug administration license for five years.
B. Elixir formula control
C. Recipe control
D. Formulation change control
E. Microbiological system control

To grant permission for the production of drugs a pharmaceutical companies need a license, from Drug administration.

One company can have two license numbers, one for the biological products (vitamin, injectables, and antibiotics) and another one for non-biological products.

Every two years the license is renewed. When a product is included under a license it is validated for five years. And after five years it is renewed.

Now, if any product's formula is changed then amendment is done. And the paper of the new formula's stability tests also has to be submitted to drug administration. If the size of the pack has to be changed then also permission has to be granted.

**Operations performed to take permission for new product**

Recipe (if from BP or USP then no sample has to be submitted but if from some other source sample has to submitted)

- Approved
- Stability study
- Packaging documents
When the product is marketed then from the 1st batch samples has to be sent to drug administration. Drug administration comes for inspection and may give some terms and conditions for the improvement of GMP, manufacturing facility etc.

**Analytical Support and Analytical Development**

It is also a very important section in IQC. This department does liaison with the research and development staff in the introduction of new products and solving of production and testing difficulties. It can be done by following two methods:

1. Stability testing
2. Analytical method development

**Purpose of stability testing:**

1. What is the condition of the product?
2. Increase the shelf-life

These tests are done on the follow types of products:

1. Marketed products
2. New products
3. Products under change control

**Functions of ASAD:**

1. New product method development
2. New product stability
3. Marketed product stability
4. Analytical method development

**Stability programs**

Categorization of stability programs:

1. Development of new products
2. Routine support of a currently marketed products
3. Change control and/or failure investigation when required

1. Development of new products:

Selection of batches:

a) For conventional dosage form (immediate release solid dosage forms, solution) and when the active ingredient are known to be stable, stability data on at least two pilot batches are acceptable.

b) For critical dosage form (prolonged release form) or when the active ingredient are known to be unstable, stability data on at least three pilot batches are required.

Test frequency and duration:

Frequency of testing should be sufficient to establish characteristics of the drugs substance. Testing under the defined long term condition will normally be every three month, over the first year every six months over the second year and then annually

1st year: 0, 3, 6, 9, 12 months
2nd year: 18, 24 months
3rd year: 36 months

Storage test conditions:

The duration of studies and storage condition required are normally:
The duration of studies and storage conditions required for temperature sensitive finished products are:

<table>
<thead>
<tr>
<th>Conditions</th>
<th>Minute, time period at submission</th>
</tr>
</thead>
<tbody>
<tr>
<td>Long term testing</td>
<td>30° C ± 2° C / 75% RH ± 5%</td>
</tr>
<tr>
<td>Short term testing</td>
<td>40° C ± 2° C / 75% RH ± 5%</td>
</tr>
</tbody>
</table>

For liquid preparations in semipermeable containers the duration of studies and storage conditions are:

<table>
<thead>
<tr>
<th>Conditions</th>
<th>Minute, time period at submission</th>
</tr>
</thead>
<tbody>
<tr>
<td>Long term testing</td>
<td>5° C ± 3° C</td>
</tr>
<tr>
<td>Short term testing</td>
<td>25° C ± 2° C / 60% RH ± 5%</td>
</tr>
</tbody>
</table>

2. Routine support of a currently marketed product:

Test frequency and duration:

Minimum sampling and testing frequency
<table>
<thead>
<tr>
<th>Category 1</th>
<th>Category 2</th>
<th>Category 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmaceutical products</td>
<td>Pharmaceutical products</td>
<td>New product on site/ products with variations</td>
</tr>
<tr>
<td><strong>Well proven stability.</strong>&lt;br&gt;Real time data for more than three years.&lt;br&gt;No more than minor degradation of potency during shelf life.&lt;br&gt;No significant change of specification testing results.&lt;br&gt;Site has produced routinely for at least three years.&lt;br&gt;No major changes occurred during last three years.</td>
<td>For all other product not in category 1 or category 3.</td>
<td>Minor changes</td>
</tr>
<tr>
<td><strong>Sampling frequency</strong></td>
<td>One lot per year.&lt;br&gt;Two lots per year in case of high volume of products.</td>
<td>One lot per year.&lt;br&gt;Two lots per year in case of high volume of products.</td>
</tr>
<tr>
<td><strong>Long term stability testing frequency</strong></td>
<td>At time 0 and then annually until the expiration date</td>
<td>At time 0 and then annually until the expiration date</td>
</tr>
<tr>
<td><strong>Accelerated testing frequency</strong></td>
<td>Not applicable</td>
<td></td>
</tr>
</tbody>
</table>

**Storage test conditions:**
The duration of studies and storage conditions required are normally:

<table>
<thead>
<tr>
<th>Conditions (retention room)</th>
<th>Minute, time period at submission</th>
</tr>
</thead>
<tbody>
<tr>
<td>Long term testing</td>
<td></td>
</tr>
<tr>
<td>Temperature: 18° C - 40° C</td>
<td>Shelf-life</td>
</tr>
<tr>
<td>Humidity: 40-80%</td>
<td></td>
</tr>
</tbody>
</table>

2. Change control and/or failure investigation when required:

Test frequency and duration:

<table>
<thead>
<tr>
<th>Category 1</th>
<th>Category 2</th>
<th>Category 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmaceutical products</td>
<td>Pharmaceutical products</td>
<td>New product on site/products with variations</td>
</tr>
<tr>
<td>Well proven stability. Real time data for more than three years. No more than minor degradation of potency during shelf life. No significant change of specification testing results. Site has produced routinely for at least three years. No major changes occurred during last three years.</td>
<td>For all other product not in category 1 or category 3.</td>
<td>Minor changes</td>
</tr>
<tr>
<td>Sampling frequency</td>
<td>One lot per year. Two lots per</td>
<td>One lot per year. Two lots per</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Storage test conditions:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Accelerated testing frequency</th>
<th>Conditions</th>
<th>Minute, time period at submission</th>
</tr>
</thead>
<tbody>
<tr>
<td>40° C ± 2° C / 75% RH ± 5%</td>
<td>6 months</td>
<td></td>
</tr>
</tbody>
</table>

**Validation of analytical procedures**

**Validation characteristics:**

<table>
<thead>
<tr>
<th>Validation characteristics</th>
<th>Minimum no.</th>
<th>Identification</th>
<th>Impurities</th>
<th>Assay</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specification</td>
<td>Not applicable</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Linearity</td>
<td>5</td>
<td>-</td>
<td>+</td>
<td>-     +</td>
</tr>
<tr>
<td>Range</td>
<td>Not applicable</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>------------------------</td>
<td>----------------</td>
<td>----</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Accuracy</td>
<td>9</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Precision</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Repeatability</td>
<td>6 or 9</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Intermediate precision/</td>
<td>2 series</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>reproducibility</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Detection limit</td>
<td>Approach</td>
<td>-</td>
<td>-5</td>
<td>+</td>
</tr>
<tr>
<td>Quantization limit</td>
<td>Approach</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>dependent</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(+ normally evaluated) (-) normally not evaluated

Revalidation:

Evaluate the need for revalidation in case of change, for example: during transfer of an analytical procedure, significant variation in the active pharmaceutical ingredient sourcing, variation in the finished product, composition of the analytical procedure.

**Microbiology Department**

For implementation of GMP microbiology department is very important. In Sanofi Aventis this department performs the followings:

a. Sterile products
   i. Sterility testing
   ii. Endotoxin testing

b. Air velocity
   i. Flow rate
c. **Laminar air flow system**
   i. Filter integrity testing

d. **Media test**
   i. Growth promotion test

e. **HVAC system**
   i. Healing condition
   ii. Ventilation system
   iii. Air conditioning system

f. **Estimation test for microorganisms**
   i. Control test
   ii. Media test
   iii. Sensitivity test
   iv. Sterility test

**To ensure safety following operations are performed**

**First**

- **ES (environmental safety)**

  Settle plate → Room soft test → Reinforce centrifugal sampler (RCS)

**Second**

- **Media test**
  o **Fungus:** dextrose, agar, soya agar
  o **Bacteria:** TS (Triptosoya assay), agar
- Sterility test
  - Sterility testing (bacteria 30-35°C in TGM, fungus 20-25°C in TSB)
  - Microbial count

- Bioassay
  - Minimum inhibitory count (MIC)

- Water count
  - Routine analysis

- Bacteria
  - Endocrine test by LAL test

- Injection
  - Free sterilization test

Liquid injection

Aseptic product  Terminally sterilized products

Direct filter  Filter

Autoclave

- Oral preparations
  - Allow 10,000 colony pathogenic organism
- **Topical preparations**
  - Allow 100 colony non-pathogenic organism

- **Machine test**
- **Appearance test**
  - Color and clarity

- **Conductivity test**
- **pH**
  - pH within 5-7

- **Nitrate**
  - Nitrate of all sample must be ≤0.2 mg/L

**Equipments used**

1. Incubator
2. Air sampler
3. Anaerobic jar
4. Centrifuge machine
5. pH meter
6. Microscope
7. Laminar air flow machine
8. Autoclave
9. LAL testing kit
10. Water bath
11. Hot oven
12. Colony counter
13. Dust collector
14. Balance
Warehouse
A centralized warehouse function is responsible for the receipt and storage of components in whatever stage of the process they are in. Store is the transit 
point of any pharmaceutical industry, as it is the place where raw material first enter, goes to manufacturing and finished products after manufacturing are also temporarily stored here before releasing to the market.

Description of the warehouse observed in Sanofi Aventis

There are several sections for the storage of separate materials

- In T4 building for non-antibiotic products:
  Warehouse 1: finished products are stored here.
  Warehouse 2: finished products are also stored here. Two separate zones are also present here for the storage of rejected products and promotional samples.
  Warehouse 3: packaging materials are stored here. (both antibiotics and non-antibiotics)
  Warehouse 4: raw materials of Aventis ltd and HMR are stored here.
  Warehouse 5: raw materials of FBL are stored here.

Cool store: there are two cool stores. One for RM and another for finished goods which are heat sensitive and the temperature is maintained below 20°C.

Foster store: here temperature is maintained between 2-8°C. Antibiotic active ingredient, vaccines (imported), Insoman etc are stored here.

For glass bottle and shipping cartoon storage, there is a separate storehouse.

- In CPR building for antibiotic products:
  Warehouse 6: active ingredient and finished products of Penicillin section are stored here. Temperature maintained below 30°C. Dispensing of RM are also
done. There is a separate RM store for antibiotic section where temperature is maintained between 15-18°C.

Warehouse 7: active ingredient and finished products of Cephalosporin section are stored here and temperature is maintained below 30°C.

**Distribution of products in raw material stores**

1. Quarantine:
The materials that has just entered into the warehouse and QC tests has not been performed are stored here.

2. Sampled:
The materials from which, samples has been taken for QC tests are stored here.

3. Approved:
The materials which, passed the QC tests and are ready to be used for manufacturing are stored here.

   In this type of materials QC attaches the expiry date. So, that the use of the material become restricted after the expiry date.

4. Rejected:
The materials which fails the QC tests and must be discarded are stored here.

**Types of products in finished product stores**

1. Awaiting for approval:
After manufacturing, finished products are labeled as “awaiting approval” are stored here.

2. Approved:
QA approved products which are ready for distribution within the warehouse are stored in separate and identified zone for easy and proper identification.
Some important factors

1. FIFO (first out first in)/FEFO strategy is followed for the release of RM to manufacturing.
2. Although materials are always taken from approved source; batch no. of the renders, manufacturing date, expiry date etc are checked before entry.
3. Complete security and prevention of pilferage of every material including the promotional materials are said to be confirmed.

Central dispensing room

According to cGMP guideline Sanofi Aventis has started a very modern and sophisticated Central Dispensing Unit. It is a specially designed area from which accurately weighed RM according to process order are dispensed to production floor. According to need RM from warehouse are taken into the central dispensing unit and then weighed under laminar air flow cabinet to prevent any type of contamination. Before weighing, the area is inspected and certified as clean.

Activities of Warehouse

Beginning of the activity:

According to market sell target is set for raw materials

The planning department does the planning which include what RM needed?, how much needed?, the frequency of intake and source.

Process order is prepared

Invoice is prepared
Negotiation is done

The materials come by seal/air depending upon the material urgency, volume and region

After the material has come the activity of the warehouse starts.

*Important note: due to the use of SAP software no material falls short.*

**Working procedures:**

Initially in the warehouse the quality of the materials are not checked

But the physical examination is done, which include whether the container is properly sealed?, if the staffs mentioned in the invoice are present or not?, if the no. of the container are same or not?

If passes

Kept in quarantine area (which are not approved yet)

The invoice data of recieval is inputted in SAP

From the SAP, Qc check if every this is ok and a manual is also sent to QC

From sampling booth the sample is sent to QC

Sample tag is attached

If the RM complies

Approval tag is attached by the QC

All approved RMs are then kept in approved area in the warehouse
All the data are uploaded in SAP

From there production unit can see and ask according to need

Warehouse follows FEFO and does the dispensing in the dispensing unit

Distribution of products from warehouse

Distribution department

Makes a Stock Transport order to warehouse according to need of depot

Picking slip is prepared by warehouse and in this case also FEFO is maintained.

According to picking slip the products are picked and from there transported to the depots by proper transportation system.
The engineering department of Sanofi Aventis consists of a group of engineers, technicians and workers.

The activities are divided into two parts according to their function

1. Maintenance
2. Project

1. Maintenance of the existing system:

The function of this section is to separate the utilities and services in the plant. They also perform the maintenance function. The utilities and services handled by this section include:

1. Electricity
2. Portable or drinking water
3. Steam boiler
4. Air compression
5. HVAC system
6. Central vacuum system
7. Calibration

Calibration section:

This section is responsible to calibrate all the instruments and machines to ensure performance and effectiveness. The general process is to calibrate the instruments and machines against a standard which is also standardized against international standards.

According to product quality management the instruments used are divided into four authentic classes.
<table>
<thead>
<tr>
<th>Class</th>
<th>Description</th>
<th>Calibration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class-1</td>
<td>These instruments are directly related to product quality of any deviation will harm the product</td>
<td>Calibrated three to six times monthly.</td>
</tr>
<tr>
<td>Class-2</td>
<td>These are standard instruments which are used to calibrate other instruments</td>
<td>Calibrated once yearly</td>
</tr>
<tr>
<td>Class-3</td>
<td>These instruments are indirectly related product quality and deviation will not harm the product.</td>
<td>Calibrated once yearly</td>
</tr>
<tr>
<td>Class-4</td>
<td>Tools, instruments used for various purposes.</td>
<td></td>
</tr>
</tbody>
</table>

Electricity:

There are three substations to provide continues electricity in the plant.

1. 500 KVA
2. 1250 KVA
3. 2000 KVA

2. Project:

The personals involved in this section design new facilities as per requirement, generation, and setup of the facilities. This section also prepares the initial documents such as design outlet, capital expenditure for machines, building or any other facilities. After completion of the project it is hand over to the maintenance department for further services.

**Main functions of the project section**

```
Machine design          Machine specification
                        ↓                           ↓
Compression                    Machine installation
                        ↓
Operation
```

95
Health Safety Environment
The concept of HSE is a modern and dynamic one. In a third world country like Bangladesh the implementation of HSE concept is rare. Among the pharmaceutical industry leaders of Bangladesh, Sanofi Aventis adopted the policy successfully.

**Mission**

The mission is to integrate HSE in all function to build a safe and healthy workplace and to ensure sustainable environment.

**HSE Policy**

The HSE policy is based on 8 guiding principles which define a framework of actions with respect to their group of employees and external partners.

1. The HSE policy is an integral part of the general policy of the group.
2. The management and the employees of the group apply the policy at all levels. Each person is aware of their roles and their personal responsibilities with regard to the prevention of accidents, risk of health and damage to the environment.
3. In all places in which the group operates it respects the applicable laws and regulations, applies expert recommendations and uses the best industrial properties.
4. Sanofi Aventis operates management system related to safety, health at work and protection of environment adapted by implementing action plans called PASS with associated control system. The process depends on basic understanding, learning from experience, working together and training.
5. Every development project and every product launch will be subjected to a safety, health and environment risk assessment integrating all the scientific and technical knowledge of the group. Such project will be developed using the best available technology throughout a product half-life.
6. Sanofi Aventis take care of economics on natural resources to minimize the residual impact of atmospheric emission of effluents or of a waste in all its industrial activities in order to preserve the natural environment.

7. With regard to its suppliers, contactors and subcontractors, Sanofi Aventis aims to promote the applications of the rules of safety and protection of environment and considers the adoption of those rules as criterion to be applied to suppliers, contactors or subcontractors.

8. Sanofi Aventis has a constructive attitude of transparency and dialogue with regard to third parties with respect to their safety, health and environmental protection policy, its achievements and its commitments.

Flow chart of chemical waste management

```
Chemical waste

Liquid waste

Solid waste

Treatment

Effluent treatment plant

Disposed outside

Alkali/ammonia treatment in case of antibiotics

Incineration
```
Effluent treatment plant

ETP is maintained properly in Sanofi Aventis, for the prevention of environmental pollution. Waste chemicals of any pharmaceuticals are responsible for the reduction of dissolved oxygen and water by increasing

- BOD (biological oxygen demand)
- COD (chemical oxygen demand)
- TDS (total dissolved solid)
- TSS (total suspended solid)
- Chlorine
- pH
- Conductivity

Waste chemicals cause environmental pollution by decreasing dissolved oxygen by oxidation.

The oxygen demand is maintained by the following method:

1. Waste chemical in ETP
2. Add nitrifying bacteria that cause breakdown of chemical
3. Oxygen penetration in water from outside
4. Urea supply in ETP for nitrifying bacteria
5. Maintaining normal limit of dissolved oxygen
6. No environmental pollution
Human Resource Management
HRM activities

- Planning
  - Mission statement
  - Organization
  - Policy formation
  - Staff strength

- Management
  - Recruitment
  - Orientation
  - Transfer/promotion
  - Leave
  - Discipline
  - Salary & wage administration
    - Increments
    - Bonus
    - Provident fund
    - Gratuity
  - Welfare
    - Insurance
    - Loans
    - Grievance
    - Handing
    - Motivation
    - Counseling
    - Canteen facilities
    - Transport
  - Separation
    - Retirement
    - Termination
    - Dismissal
- Exit formalities
- Resignation

- Development
  - Approval
  - Training
  - Rewards

- MIS
  - Record keeping
  - Reporting
  - Compensation
Findings
The people of Sanofi-aventis are very cooperative.

The personal protective equipments are used properly as per requirement.

All equipments are validated and the expiry dates of validation are frequently checked by the officers so, that revalidation is done timely.

Safety card (providing safety instructions to machine operators) is present on all equipments.

List of authorized persons, the names of the ones who are only permitted to operate the machine are also present on the equipment.

Labeling (describing state of operation, for example: machine label, to be cleaned, cleaned, under test etc) are attached to machine.

Machine log book is maintained properly to avoid any deviation.

Cleaning of room and machines are done after each batch manufacturing and the room is labeled cleaned, to be cleaned.

Even the name of the previous product is mentioned on the room so that specified cleaning procedure can be applied.

Regular inspection is done from QA to see whether the environment to right.

Sample are regularly sent to the IQC for IPC and also people from IQC come to take samples.

Proper protective growing system for all operating procedures.

SOPs are present in the production areas and they are maintained and followed properly.
They have internal audit as well as from other companies (whose drugs are manufactured in this site) frequently.

As the site is a very old one the layout is not an ideal one but yet GMP maintained and the employees follow the requirements properly.

Three separate premises for the three antibiotics as per GMP requirement.

Different gowning system for different antibiotic production.

Two separate lab systems for Cephalosporin and Penicillin, to avoid contamination.

All the labs are well equipped and proper maintenance is also present.

Officers/analysts must wear lab coat, eye protector before entering the working area in the labs.

COD, BOD etc tests are performed before the waste disposal.

All the chemicals in the lab are kept separately in group according to their use and character and all are labeled, for example:

- Hazardous chemicals
- Working chemicals
- Mobile phase and indicators
- Inflammables solvents
- Corrosive liquids

While running some specific equipments (for example particle counter) laminar air flow is used to get accurate result.

Eye wash shower is present in the lab as well as in production area.
The site map is present in almost every area to avail quick exit in case of any emergency.

The exit signs with arrows indicating the direction are present and the signs also glow in the dark to facilitate evacuation.

Every work is documented to practice GMP.

Good food facilities and interval between works helps the employees to remain motivated and work properly.

Training programs are arranged quite frequently to improve the quality.

Safety places are present in the site so people can gather there in case of any emergency.

Sanofi-aventis provide good transport facility for all the employees.

Up to date official books (USP, BP etc) are present in the IQC department.

The site is very green, also has ponds which makes it an environment friendly site.

The company treats its workers as asset.

It has a very sophisticated and modern central dispensing center.

It provides proper in plant medical facilities and a medical center is also available.
Conclusion
Sanofi-aventis has a really strong goodwill. The company provides and
ensures quality medicines. They maintain GMP properly and believe in
documentation. They have a very strong quality control, engineering, storage
system helping them to maintain the quality of the drugs. Sanofi-aventis also
has proper system for disposal of the wastes to protect the nature.

So far the company is in good condition and they can reach even higher rank
among the leading multinational companies if they continue to provide proper
service and quality drugs.